repolarize them into an antitumor phenotype is considered as a novel strategy for cancer treatments in recent years. For discovering novel compounds that target TAMs, a series of ureido tetrahydrocarbazole derivatives were designed, synthesized and evaluated both in vitro and in vivo. Among them, compound 23a was found to dose-dependently repolarize TAMs from M2 to M1 both in vitro and in vivo. And more
肿瘤相关巨噬细胞(TAM)是肿瘤微环境(TME)的重要组成部分之一。TAM的极化特性驱使它们以M1(抗肿瘤)和M2(肿瘤前)表型之间的状态渗透和活跃。通过靶向TAM将小分子药物重新极化为抗肿瘤表型来开发小分子药物被认为是近年来治疗癌症的新策略。为了发现靶向TAM的新型化合物,在体外和体内设计,合成和评估了一系列
脲基四氢
咔唑衍
生物。其中,发现化合物23a在体外和体内均可剂量依赖性地将TAM从M2重新极化为M1。更重要的是 体内实验还表明,化合物23a能够显着抑制LLC小鼠模型的肿瘤生长。此外,化合物23a与抗PD-1
抗体的协同作用比任何一种体内使用都具有更优异的抗肿瘤作用。